Truist raised the firm’s price target on Sabra Health Care (SBRA) to $18 from $17 and keeps a Hold rating on the shares. The risk of recession has increased and the 10-year Treasury rate has fallen since the firm’s downgrade of the stock in January, the analyst tells investors in a research note. Notwithstanding risks to Medicaid funding, select healthcare REITs might generally be relatively defensive within the sector if macroeconomic trends continue to worsen, Truist adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Healthcare Reit Projects Positive 2025 Amid Growth
- Sabra Healthcare REIT Reports Strong Q4 2024 Results
- Sabra Healthcare REIT: Hold Rating Amid Stable Financials and Cautious Growth Strategy
- Sabra Health Care reports Q4 AFFO 36c, consensus 36c
- Sabra Health Care sees FY25 AFFO $1.47-$1.50, consensus $1.49
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue